- GlaxoSmithKline PLC stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
GlaxoSmithKline PLC stock price
GlaxoSmithKline PLC latest news:
Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed
LONDON, Feb 8 (Reuters) - GlaxoSmithKline has won
another reprieve for its blockbuster Advair lung drug after U.S.
regulators delayed approval of a generic copy from Novartis's
BRIEF-GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences
Glaxosmithkline Plc(GSK): * VIIV FILES PATENT INFRINGEMENT LITIGATION. * Glaxosmithkline Plc(GSK) - VIIV âANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADAâ Source text for Eikon: Further company coverage:
GSK cheers investors with asthma drug sales, big dividend
Drugmaker GlaxoSmithKline sank to a fourth-quarter loss of 546 million pounds ($758 million) from a profit of 257 million pounds a year earlier, as it dealt with U.S. tax changes.
BRIEF-ACCC Institutes Proceedings Against GSK, Novartis
Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.
GSK starts big African study of injectable drug to prevent HIV
ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.
BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women
* VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND
LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF
HIV INFECTION IN SEXUALLY ACTIVE WOMEN
Source text for Eikon:
Further company coverage:
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca will be priced at about $31,000-a-year, comparable to GlaxoSmithKline's three-drug HIV regimen Triumeq, suggesting that Juluca won't "'break the price' in HIV," said EvercoreISI analyst Umer Raffat. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Global Brass and Copper HoldingsBRSS
Global Cash Access HoldingsGCA
Global High Income Dollar FundGHI
Global Net LeaseGNL
Global Partners LPGLP
Global Payments Inc.GPN
Global Power Equipment Group IncGLPW
Global Ship LeaseGSL
Global Ship LeaseGSL^B